Sheraton Boston | October 13-14, 2017
9:00 AM- 5:30 PM
Exhibit Set-up
1:00 PM- 5:30 PM
Registration
FRIDAY, OCTOBER 13, 2017
7:00 AM – 8:00 AM
CONTINENTAL BREAKFAST
Exhibit Hall, Constitution Ballroom
8:00 AM – 10:55 AM
SESSION I. STATE OF THE ART IN PROSTATE CANCER CARE:
Current and Potential Impact of Precision Diagnostics on Precision Care
10:55 AM – 2:00 PM
SESSION II. INCREASING BENEFITS AND REDUCING RISKS OF SCREENING WITH NOVEL DIAGNOSTIC APPROACHES:
Improving Risk Assessment and Patient Selection for Biopsies and Tissue Sampling Prior to Diagnosis of Prostate Cancer
2:00 PM – 6:00 PM
SESSION III. DIAGNOSTIC ASSESSMENT OF MEN WITH PROVEN PROSTATE CANCER:
Improving Prediction of Progression, Staging, and Patient Selection for Treatment
7:00 PM – 9:30 PM
Dinner Reception, Poster Competition and Industry Leadership Session on Innovation
SATURDAY, OCTOBER 14, 2017
7:00 AM – 8:00 AM
CONTINENTAL BREAKFAST
Exhibit Hall, Constitution Ballroom
8:00 AM – 8:55 AM
SESSION IV. PRECISION DIAGNOSTICS AND EMERGING ROLE OF FOCAL TREATMENT:
Patient Selection, Monitoring, and Outcomes
8:55 AM – 12:30 PM
SESSION V. PRECISION ONCOLOGY AND ADVANCED PROSTATE CANCER
12:30 PM – 1:15 PM
LUNCH
Exhibit Hall, Constitution Ballroom
1:15 PM – 2:00 PM
SUMMARY PANEL DISCUSSION:
Emerging Clinical Utility of Precision Diagnostics and Expediting Transfer of Promising Technologies from Laboratories to Clinics
2:00 PM
Adjourn
9:00 am – 5:30 pm
Exhibit Setup
1:00 pm – 5:30 pm
Registration
8:00 am
INTRODUCTION AND STATEMENT OF PURPOSE
.
Faina Shtern, MD, President and CEO, AdMeTech Foundation
.
.
.
SESSION I
STATE OF THE ART IN PROSTATE CANCER CARE:
Current and Potential Impact of Precision Diagnostics on Precision Care
Moderators:
.
Adam Kibel, MD, Elliot Carr Cutler Professor of Surgery, Harvard Medical School; and Chief of Urology, Brigham and Women’s Hospital and Dana Farber Cancer Institute
Hedvig Hricak, MD, PhD, Carroll and Milton Petrie Chair, Department of Radiology, Memorial Sloan Kettering Cancer Center
.
Peter Nelson, MD, Endowed Chair for Prostate Cancer, Fred Hutchison Cancer Research Center, and Professor of Oncology, University of Washington
.
8:10 am
Screening
.
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
.
8:25 am Q & A
8:45 am Q & A
8:50 am
Urology Perspective on Baseline PSA and Early Detection of Prostate Cancer: Guidelines of the National Comprehensive Cancer Network
Adam Kibel, MD
.
9:05 am
Urology Perspective on Low-Risk Prostate Cancer and the Emerging Impact of In Vitro Diagnostics, In Vivo Imaging, and Radiogenomics
Peter Pinto, MD, Head of Prostate Cancer Section, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
.
.
9:20 am Q & A
9:25 am
Radiation Oncology Perspective on High-Risk and Recurrent Prostate Cancer – and the Emerging Role of Molecular Diagnostics, Imaging, and Radiogenomics
Alan Pollack, MD, PhD, Professor and Chairman of Radiation Oncology, University of Miami Miller School of Medicine
.
9:40 am
Keynote Address: Medical Oncology Perspective on Precision Diagnosis and Liquid Biopsy of Advanced Prostate Cancer
David Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine
.
.
9:55 am Q & A
10:00 am- 10:20 am
Coffee Break
10:20 am Pathology Perspective
SESSION II
INCREASING BENEFITS AND REDUCING RISKS OF SCREENING WITH NOVEL DIAGNOSTIC APPROACHES:
Improving Risk Assessment and Patient Selection for Biopsies and Tissue Sampling Prior to Diagnosis of Prostate Cancer
Moderators:
.
Richard Babayan, MD, Professor of Surgery and Chairman of Urology, Boston University School of Medicine
.
.
.
.
Sigrid Carlsson, MD, PhD, MPH
.
.
10:55 am
Emerging Fluid-Based Molecular Diagnostics
.
Francesca Demichelis, PhD, Associate Professor and Head of Computational Oncology Laboratory, Centre for Integrative Biology, University of Trento, Italy
.
11:10 am
Liquid Biopsies: Definition and Clinical Utility
.
Michael Donovan, MD, PhD, Professor of Pathology, Mount Sinai Medical Center
.
11:25 am Q & A
11:30 am
Advanced Ultrasound
.
Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada
.
.
.
11:45 am
Multi-Parametric MRI and Multi-Modality Image Fusion: Emerging Data and the Role of PI-RADS
.
Peter Choyke, MD, Director, Molecular Imaging, National Cancer Institute, National Institutes of Health
.
.
12:00 pm Q & A
12:05 pm
In Vitro Diagnostics- and their Integration with In Vivo Imaging
.
Sanoj Punnen, MD, Assistant Professor of Surgery, University of Miami Miller School of Medicine
12:20 pm Q & A
12:30 pm Lunch Break
1:30 pm
Panel Discussion on Risk Assessment Prior to Diagnosis of Prostate Cancer
Moderators, Speakers, and –.
.
Minhaj Siddiqui, MD, Assistant Professor of Surgery and Chief of Urologic Oncology, University of Maryland; and
.
.
.
.
.
Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
.
.
.
Stephen Zappala, MD, Assistant Clinical Professor of Urology, Tufts University School of Medicine
.
.
.
SESSION III
DIAGNOSTIC ASSESSMENT OF MEN WITH PROVEN PROSTATE CANCER:
Improving Prediction of Progression, Staging, and Patient Selection for Treatment
Moderators:
.
Peter Pinto, MD
.
.
.
.
.
Alan Pollack, MD
.
.
.
.
.
Clare Tempany, MD, Ferenc Jolesz MD Professor of Radiology Harvard Medical School and Vice Chair for Radiology Research, Brigham and Women’s Hospital, Harvard Medical School
.
.
.
2:00 pm In Vivo Imaging and Radiomics
2:00 pm
Multi-Modality Imaging and Tumor Heterogeneity
.
Baris Turkbey, MD, Associate Research Physician, Molecular Imaging Program, National Cancer Institute
.
.
.
2:15 pm
Molecular Imaging
Mehrdad Alemozaffar, MD, Assistant Professor of Urology, Emory University School of Medicine
.
.
.
2:30 pm Q & A
2:35 pm
Radiomics/Quantitative Imaging and Active Surveillance
.
Masoom Haider, MD, Professor and Radiologist-in-Chief, Sunnybrook Health Sciences Center, University of Toronto, Canada
.
.
2:50 pm Q & A
2:55 pm Tissue-Based Genomics and Phenotypic Biomarkers
2:55 pm
Pathology Perspective
.
Angelo DeMarzo, MD, PhD
.
.
.
3:10 pm Q & A
3:15 pm
Public Health Perspective
.
Jennifer Rider, ScD, MPH, Assistant Professor, Department of Epidemiology, Boston University School of Public Health
.
.
.
3:30 pm Q & A
3:35 pm
Urologic Perspective: Live-Single-Cell Phenotypic Biomarkers and Precision Oncology
.
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Medical Director for Associated Medical Professionals
.
.
3:50 pm Q & A
3:50 pm Coffee Break
4:15 pm Radiogenomics: Emerging and Future Impact on Patient Evaluation, Treatment Selection and Monitoring
5:00 pm – 6:00 pm
Panel Discussion on Diagnostic Evaluation of Men with Proven Prostate Cancer
Speakers, Moderators, and-
.
Nicolas Bloch, MD, Chief of MRI and Associate Professor of Radiology, Boston University School of Medicine;
.
.
.
.
Michael Donovan, MD
.
.
.
.
.
Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School;
.
.
.
Susan Noworolski, PhD, Associate Professor, Department of Radiology, UCSF;
.
.
.
.
.
Amita Shukla-Dave, PhD, Deputy Service Chief for Predictive Informatics and Director, Quantitative Imaging, Memorial Sloan Kettering Cancer Center; and
.
.
.
Srinivas Vourganti, MD, Urologic Oncologist and Assistant Professor, Rush University Medical Center
.
.
.
.
7:00 pm – 9:30 pm
Dinner Reception, Poster Competition and Industry Leadership Session on Innovation
7:30 pm
David Gauden, PhD, Chief Scientific Officer, Blue Earth Diagnostics, United Kingdom
7:40 pm
Heinrich Von Busch, PhD, Product Owner, Artificial Intelligence for Oncology Imaging, Siemens Healthineers, Germany
7:55 pm
Antoine Leroy, PhD, President, Koelis, France
8:00 pm
Brian Liu, PhD, Medical Science Liaison-Urology, Myriad, USA
8:05 pm
Randall Jones, D.E. (PhD, MBA), Founder and CEO, ScanMed, USA
8:10 pm
Jason Polzin, PhD, General Manager, GE MR Applications Segment, USA
8:15 pm
Jerrold Wen, VP for Engineering, Exact Imaging, Canada
8:20 pm
Bela Denes, MD, Senior Director, Medical Affairs Urology, Genomic Health
8:25 pm – 9:30 pm Poster Session and Announcement of the Competition Winners
SESSION IV
PRECISION DIAGNOSTICS AND EMERGING ROLE OF FOCAL TREATMENT:
Patient Selection, Monitoring, and Outcomes
Moderators:
.
Jason Efstathiou, MD, D.Phil., Associate Professor, Harvard Medical School & Director, Genitourinary Division, Massachusetts General Hospital
.
.
.
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
.
.
.
.
8:15 am Q & A
8:20 am
Overview of Laser Treatment
.
Aytekin Oto, MD, MBA, Professor of Radiology and Surgery, Section Chief, Abdominal Imaging; Director, Body MR Imaging, University of Chicago Medical Center
.
.
.
8:35 am
Overview of Cryoablation and Focused Ultrasound
.
Jurgen Futterer, MD, PhD, Interventional Radiologist, Nijmegen Medical Center and Professor, University of Twente, The Netherlands
.
.
8:50 am Q & A
8:55 am
Overview
.
Wassim Abida, MD, PhD, Staff Oncologist, Memorial Sloan Kettering Cancer Center
.
9:10 am Q & A
9:15 am
Germline Mutations and Germline Testing in Advanced Prostate Cancer
.
Peter Nelson, MD, Endowed Chair for Prostate Cancer, Fred Hutchison Cancer Research Center, and Professor of Oncology, University of Washington
.
.
9:30 am Q & A
9:50 am Q & A
9:55 am
Genomic Testing
.
Adam Feldman, MD, MPH, Assistant Professor and Director, Combined Harvard Urologic Oncology Fellowship, Harvard Medical School and Assistant in Urology, Massachusetts General Hospital
.
.
10:10 am Q & A
10:15 am- 10:35 am
Coffee Break
10:35 am Molecular Imaging, Nuclear Medicine and PET
10:35 am
Overview
.
Heather Jacene, MD, Assistant Professor of Radiology and Associate Program Director, Brigham and Women’s Joint Program in Nuclear Medicine, Harvard Medical School
.
.
.
10:50 am
PSMA Imaging: Current and Potential Role in Patient Care
.
Steven Rowe, MD, PhD, Assistant Professor of Radiology, Johns Hopkins University School of Medicine
.
.
.
11:05 am
Experience with PSMA PET at UCSF
.
Thomas Hope, MD, Assistant Professor of Residence in the Abdominal Imaging and Nuclear Medicine, Department of Radiology, University of California, San Francisco
.
.
.
11:20 am Q & A
11:25 am
Amino Acid Imaging for Recurrent Prostate Cancer
.
Ashesh B. Jani, MD, MSEE, Professor, Department of Radiation Oncology, Emory University
.
.
.
11:40 am
Multi-Modality Imaging in Recurrent and Advanced Disease
.
Peter Choyke, MD
.
.
.
11:55 am Q & A
12:30 pm
Lunch Break
1:15 – 2:00 PM
SUMMARY PANEL DISCUSSION:
Expediting Transfer of Promising Technologies from Laboratories to Clinics
Moderators and Speakers
Session Chairs
.
Mark Buzza, PhD, MBA, Director, Global Biomedical Research Programs, Movember Foundation, Australia
.
.
.
Faina Shtern, MD
.
.
1:15 pm
Perspective from Movember: Identifying and Filling Clinical Gaps and Needs
.
Mark Buzza, PhD, MBA
.
.
1:25 pm
Perspective from the USA Vice President Joe Biden’s Cancer Moonshot Initiative: National Priorities and Infrastructure, Regulatory and Reimbursement Policy
.
Richard Frank, MD, Chief Medical Officer, Siemens Healthineers, USA
.
.
1:35 pm
Comments
.
Peter Choyke, MD
.
.
.
.
Minhaj Siddiqui, MD
.
.
1:40 pm
NCCN Clinical Guidelines for Early Detection of Prostate Cancer
.
Preston Sprenkle, MD
.
.
1:50 pm
Perspective from AdMeTech: Integration of Research, Medical Education, Public Awareness and Advocacy for Changing Standards of Prostate Cancer Care
.
Faina Shtern, MD
.
.
2 PM ADJOURN